Capricor Therapeutics is suing its Japanese partner, Nippon Shinyaku and NS Pharma, for mishandling the launch preparations of their Duchenne muscular dystrophy cell therapy. This legal battle highlights risks in biotech partnerships and could affect how developers approach collaborations and pricing strategies for new therapies. Watch for potential changes in Capricor’s market valuation and future partnership dynamics.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



